Certolizumab Can Also Be Effective in Monotherapy for the Treatment of Rheumatoid Arthritis Patients

Pedro Santos-Moreno,1 Susan Martinez,2 Linda Ibatá,2 Laura Villarreal,1 Manuel Rivero,3 Adriana Rojas-Villarraga4 1Rheumatology, Biomab IPS, Bogotá, DC, Colombia; 2Epidemiology, Biomab IPS, Bogotá, DC, Colombia; 3Pharmacy, Biomab IPS, Bogotá, DC, Colombia; 4Rheumatology, Research División, Fundación...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Santos-Moreno P, Martinez S, Ibatá L, Villarreal L, Rivero M, Rojas-Villarraga A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	rheumatoid arthritis treatment anti-tnfs certolizumab monotherapy Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/4fe734f522e14ae7a2031af7e86d303a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4fe734f522e14ae7a2031af7e86d303a
record_format	dspace
spelling	oai:doaj.org-article:4fe734f522e14ae7a2031af7e86d303a2021-12-02T18:37:21ZCertolizumab Can Also Be Effective in Monotherapy for the Treatment of Rheumatoid Arthritis Patients1177-5491https://doaj.org/article/4fe734f522e14ae7a2031af7e86d303a2021-10-01T00:00:00Zhttps://www.dovepress.com/certolizumab-can-also-be-effective-in-monotherapy-for-the-treatment-of-peer-reviewed-fulltext-article-BTThttps://doaj.org/toc/1177-5491Pedro Santos-Moreno,1 Susan Martinez,2 Linda Ibatá,2 Laura Villarreal,1 Manuel Rivero,3 Adriana Rojas-Villarraga4 1Rheumatology, Biomab IPS, Bogotá, DC, Colombia; 2Epidemiology, Biomab IPS, Bogotá, DC, Colombia; 3Pharmacy, Biomab IPS, Bogotá, DC, Colombia; 4Rheumatology, Research División, Fundación Universitaria de Ciencias de la Salud – FUCS, Bogotá, DC, ColombiaCorrespondence: Pedro Santos-MorenoRheumatology, Biomab IPS, Calle 48 # 13-86, Bogotá, ColombiaEmail pedrosantosmoreno@hotmail.comObjective: Although it is known that methotrexate (MTX) increases the effectiveness of biological drugs (mainly anti-TNFs) in patients with rheumatoid arthritis (RA), in real life, it is known that many patients using anti-TNFs are on monotherapy due to many causes. This article compares the effectiveness of certolizumab as monotherapy as combined with MTX or leflunomide (LFN) in RA patients with failure to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in a real-world setting.Methods: A retrospective observational cohort study was conducted at a specialized centre for RA management in Colombia. Patients treated with certolizumab as monotherapy or in combination with MTX, LFN, or MTX+LFN, between 2011 and 2020 with a minimum 3-month follow-up were included. Demographics and RA clinical characteristics were recorded; effectiveness was assessed as the improvement in Disease Activity Score (DAS28) getting remission or low disease activity at 3, 6, and 12 months of treatment.Results: A total of 181 patients were included, 24 received certolizumab as monotherapy, 62 certolizumab plus MTX, 47 certolizumab plus LFN and 48 certolizumab plus MTX+LFN. At 3 months of follow-up, 80% of the patients showed decreased disease activity, with no significant differences between groups; at 12 months of treatment, response in certolizumab monotherapy group was 94.4% compared to 81.8% in combination with MTX, 80.5% in combination with LFN and 51.4% in combination with MTX+LFN. Response at 3 months (OR 4.04; 95% CI 1.28– 12.69) and positive anti-CCP (OR 3.83; 95% CI 1.11– 13.21) were associated with 12-month response.Conclusion: Certolizumab seems to be effective as monotherapy in the treatment of RA patients with failure to csDMARDs.Keywords: rheumatoid arthritis, treatment, anti-TNFs, certolizumab, monotherapySantos-Moreno PMartinez SIbatá LVillarreal LRivero MRojas-Villarraga ADove Medical Pressarticlerheumatoid arthritistreatmentanti-tnfscertolizumabmonotherapyMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 15, Pp 433-440 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	rheumatoid arthritis treatment anti-tnfs certolizumab monotherapy Medicine (General) R5-920
spellingShingle	rheumatoid arthritis treatment anti-tnfs certolizumab monotherapy Medicine (General) R5-920 Santos-Moreno P Martinez S Ibatá L Villarreal L Rivero M Rojas-Villarraga A Certolizumab Can Also Be Effective in Monotherapy for the Treatment of Rheumatoid Arthritis Patients
description	Pedro Santos-Moreno,1 Susan Martinez,2 Linda Ibatá,2 Laura Villarreal,1 Manuel Rivero,3 Adriana Rojas-Villarraga4 1Rheumatology, Biomab IPS, Bogotá, DC, Colombia; 2Epidemiology, Biomab IPS, Bogotá, DC, Colombia; 3Pharmacy, Biomab IPS, Bogotá, DC, Colombia; 4Rheumatology, Research División, Fundación Universitaria de Ciencias de la Salud – FUCS, Bogotá, DC, ColombiaCorrespondence: Pedro Santos-MorenoRheumatology, Biomab IPS, Calle 48 # 13-86, Bogotá, ColombiaEmail pedrosantosmoreno@hotmail.comObjective: Although it is known that methotrexate (MTX) increases the effectiveness of biological drugs (mainly anti-TNFs) in patients with rheumatoid arthritis (RA), in real life, it is known that many patients using anti-TNFs are on monotherapy due to many causes. This article compares the effectiveness of certolizumab as monotherapy as combined with MTX or leflunomide (LFN) in RA patients with failure to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in a real-world setting.Methods: A retrospective observational cohort study was conducted at a specialized centre for RA management in Colombia. Patients treated with certolizumab as monotherapy or in combination with MTX, LFN, or MTX+LFN, between 2011 and 2020 with a minimum 3-month follow-up were included. Demographics and RA clinical characteristics were recorded; effectiveness was assessed as the improvement in Disease Activity Score (DAS28) getting remission or low disease activity at 3, 6, and 12 months of treatment.Results: A total of 181 patients were included, 24 received certolizumab as monotherapy, 62 certolizumab plus MTX, 47 certolizumab plus LFN and 48 certolizumab plus MTX+LFN. At 3 months of follow-up, 80% of the patients showed decreased disease activity, with no significant differences between groups; at 12 months of treatment, response in certolizumab monotherapy group was 94.4% compared to 81.8% in combination with MTX, 80.5% in combination with LFN and 51.4% in combination with MTX+LFN. Response at 3 months (OR 4.04; 95% CI 1.28– 12.69) and positive anti-CCP (OR 3.83; 95% CI 1.11– 13.21) were associated with 12-month response.Conclusion: Certolizumab seems to be effective as monotherapy in the treatment of RA patients with failure to csDMARDs.Keywords: rheumatoid arthritis, treatment, anti-TNFs, certolizumab, monotherapy
format	article
author	Santos-Moreno P Martinez S Ibatá L Villarreal L Rivero M Rojas-Villarraga A
author_facet	Santos-Moreno P Martinez S Ibatá L Villarreal L Rivero M Rojas-Villarraga A
author_sort	Santos-Moreno P
title	Certolizumab Can Also Be Effective in Monotherapy for the Treatment of Rheumatoid Arthritis Patients
title_short	Certolizumab Can Also Be Effective in Monotherapy for the Treatment of Rheumatoid Arthritis Patients
title_full	Certolizumab Can Also Be Effective in Monotherapy for the Treatment of Rheumatoid Arthritis Patients
title_fullStr	Certolizumab Can Also Be Effective in Monotherapy for the Treatment of Rheumatoid Arthritis Patients
title_full_unstemmed	Certolizumab Can Also Be Effective in Monotherapy for the Treatment of Rheumatoid Arthritis Patients
title_sort	certolizumab can also be effective in monotherapy for the treatment of rheumatoid arthritis patients
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/4fe734f522e14ae7a2031af7e86d303a
work_keys_str_mv	AT santosmorenop certolizumabcanalsobeeffectiveinmonotherapyforthetreatmentofrheumatoidarthritispatients AT martinezs certolizumabcanalsobeeffectiveinmonotherapyforthetreatmentofrheumatoidarthritispatients AT ibatal certolizumabcanalsobeeffectiveinmonotherapyforthetreatmentofrheumatoidarthritispatients AT villarreall certolizumabcanalsobeeffectiveinmonotherapyforthetreatmentofrheumatoidarthritispatients AT riverom certolizumabcanalsobeeffectiveinmonotherapyforthetreatmentofrheumatoidarthritispatients AT rojasvillarragaa certolizumabcanalsobeeffectiveinmonotherapyforthetreatmentofrheumatoidarthritispatients
_version_	1718377797295013888

Certolizumab Can Also Be Effective in Monotherapy for the Treatment of Rheumatoid Arthritis Patients

Ejemplares similares